Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: A potential strategy for uveal melanoma

Melanoma Research

Volumn 15, Issue 3, 2005, Pages 147-153

  Klisovic, Dino D ^a,c   Klisovic, Marko I ^a   Effron, David ^b   Liu, Shujun ^a   Marcucci, Guido ^a   Katz, Steven E ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Depsipeptide; Histone deacetylase inhibitor; Matrix metalloproteinase (MMP); Tissue inhibitor of matrix metalloproteinase (TIMP); Uveal melanoma

Indexed keywords

DEPSIPEPTIDE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ARTICLE; BASEMENT MEMBRANE; CANCER CELL CULTURE; CELL MIGRATION; DOSE RESPONSE; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; RISK FACTOR; UPREGULATION; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; DEPSIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; MELANOMA; METALLOENDOPEPTIDASES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; UVEAL NEOPLASMS;

EID: 20544473454     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200506000-00002     Document Type: Article

References (33)

1. Einhorn LH, Burgess MA, Gottlieb JA. Metastatic patterns of choroidal melanoma. Cancer 1974; 34:1001-1004.
2. Lorigan JG, Wallace S, Mavligt GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. Am J Radiol 1991; 157:1279-1281.
3. Jensen OA. Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta Ophthalmol (Copenh) 1982; 60:161-182.
4. Donoso LA, Shields JA, Augsburger JA, Orth DH, Johnson P. Metastatic uveal melanoma: diffuse hepatic metastasis in patient with concurrent normal serum enzyme levels and liver scan (letter). Arch Ophthalmol 1985; 103:758.
5. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581.
6. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003; 13:303-306.
7. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumor invasion and metastasis. Eur J Cancer 2000; 36:1621-1630.
8. John A, Tuszynski G. The role of matrix metalloproteinase in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001; 7:14-23.
9. Väisänen A, Kallioinen M, von Dickhoff K, Laatikainen L, Höyhtyä M, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) immunoreactive protein - a new prognostic marker in uveal melanoma? J Pathol 1999; 188:56-62.
10. El-Shabrawi Y, Ardjomand N, Radner H, Ardjomad N. MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma. J Pathol 2001; 194:201-206.
11. Beliveau A, Berube M, Rousseau A, Pelletier G, Guérin SL. Expression of integrin α5β1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma. Invest Ophthalmol Vis Sci 2000; 41:2363-2372.
12. Seftor REB, Seftor EA, Koshikawa N, Meltzer PS, Gardner LM, Bilban M, et al. Cooperative interactions of laminin 5 γ2 chain, matrix metalloproteinase-2 and membrane type-1/matrix metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 2001; 61:6322-6327.
13. Ozerdem U, Mach-Hofacre B, Varki N, Folberg R, Mueller AJ, Ochabski R, et al. The effect of prinomastat (AG3340), a synthetic inhibitor of matrix metalloproteinase, on uveal melanoma rabbit model. Curr Eye Res 2002; 24:86-91.
14. Mizzen CA, Allis CD. Linking histone acetylation to transcriptional regulation. Cell Mol Life 1998; 54:6-20.
15. Klisovic DD, Katz SE, Effron D, Klisovic MI, Wickham J, Parthun MR, et al. Depsipeptide (FR901228) inhibits proliferation and induces apoptosis in primary and metastatic human uveal melanoma cell lines. Invest Ophthalmol Vis Sci 2003; 44:2390-2398.
16. Hendrix MJ, Seftor EA, Seftor RE, Gardner LM, Boldt HC, Meyer M, et al. Biologic determinants of uveal melanoma metastatic phenotype: role of intermediate filaments as predictive markers. Lab Invest 1998; 78:153-163.
17. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev 1999; 18:359-375.
18. Hendrix MJ, Seftor EA, Seftor RE, Fidler IJ. A simple quantitative assay for studying the invasive potential of high and low human metastatic variants. Cancer Lett 1987; 38:137-147.
19. Affeldt JC, Minckler DS, Azen SP, Yeh L. Prognosis in uveal melanoma with extrascleral extension. Arch Ophthalmol 1980; 98:1975-1979.
20. Seddon JM, Albert DM, Lavin PT, Robinson N. A prognostic factor study of disease-free interval and survival following enucleation for uveal melanoma. Arch Ophthalmol 1983; 101:1894-1899.
21. Seddon JM, Polivogianis L, Hsieh CC, Albert DM, Gamel JW, Gragoudas ES. Death from uveal melanoma: number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. Arch Ophthalmol 1987; 105:81-86.
22. Augsburger JJ, Schneider RR, Terrto C, Gamel JW, Shields JA. Clinical parameters predictive of enlargement of melanocytic choroidal lesions. Br J Ophthalmol 1989; 73:911-917.
23. Folberg R, Rummelt V, Parys-Van Gindedeuren R, Hwang T, Woolson RF, Pe'er J, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology 1993; 100:1389-1398.
24. McLean IW, Ainbinder DJ, Gamel JW, McCurdy JB. Choroidal-ciliary body melanoma: a multivariate survival analysis of tumor location. Ophthalmology 1995; 102:1060-1064.
25. Coleman K, Baak JP, van Diest JP, Mullaney J. Prognostic value of morphometric features and the Callender classification in uveal melanomas. Ophthalmology 1996; 103:1634-1641.
26. Char DH, Kroll S, Phillips TL. Uveal melanoma: growth rate and prognosis. Arch Ophthalmol 1997; 115:1014-1018.
27. McLean IW, Keefe KS, Burnier MN. Uveal melanoma: comparison of the prognostic value of fibrovascular loops, mean of the ten largest nucleoli, cell type and tumor size. Ophthalmology 1997; 104:777-780.
28. Folberg R, Mehaffey M, Gardner LM, Meyer M, Rummelt V, Pe'er J. The microcirculation of choroidal and ciliary body melanomas. Eye 1997; 11:227-238.
29. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe'er J, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 1999; 155:739-752.
30. Ellerbroek SM, Stack S. Membrane associated matrix metalloproteinases in metastasis. BioEssays 1999; 21:940-949.
31. Alvarez OA, Carmichael DF, DeCleck YA. Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant tissue inhibitor of matrix metalloproteinases. J Natl Cancer Inst 1990; 82:589-595.
32. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, et al. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243:947-950.
33. DeClerck YA, Perez N, Shrimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of matrix metalloproteinases. Cancer Res 1992; 52:701-708.